Related Experiment Video

Updated: Aug 31, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1000

The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease

Ayse Seda Yazgili1, Frédéric Ebstein2, Silke Meiners3,4,5

  • 1Comprehensive Pneumology Center (CPC), Helmholtz Center Munich, Max-Lebsche Platz 31, 81377 Munich, Germany.

Biomolecules
|August 26, 2022
PubMed

Insights

The proteasome activator PA200 (PSME4) is crucial for protein homeostasis and a potential cancer therapeutic target. Understanding its biology may lead to new treatments with fewer side effects than current proteasome inhibitors.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Proteomics

Background:

  • Proteasomes are vital for protein homeostasis and are therapeutic targets for diseases like cancer.
  • Current proteasome inhibitors cause side effects, limiting their use.
  • Targeting specific proteasome complexes requires understanding their unique biology.

Purpose of the Study:

  • To discuss the structure, biology, and function of the alternative proteasome activator PA200 (PSME4).
  • To summarize evidence of PA200 (PSME4) dysregulation in human diseases.
  • To highlight PA200 (PSME4) as a potential therapeutic target for cancer.

Main Methods:

  • Literature review of proteasome biology.
  • Analysis of existing research on PA200 (PSME4) structure and function.
  • Compilation of evidence for PA200 (PSME4) involvement in human diseases.

Main Results:

  • PA200 (PSME4) is an alternative proteasome activator with distinct biological roles.
  • Dysregulation of PA200 (PSME4) is observed in various human diseases, including cancer.
  • PA200 (PSME4) presents a novel therapeutic avenue.

Conclusions:

  • PA200 (PSME4) is an important regulator of proteasome function.
  • Further research into PA200 (PSME4) biology is warranted.
  • PA200 (PSME4) holds promise as a targeted therapeutic strategy for cancer.
Keywords:
PA200PSME4proteasome

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K
Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein10:25

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein

Published on: November 10, 2012

16.8K

Related Concept Videos

The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.9K
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
911
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
12.7K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.5K
The Unfolded Protein Response01:37

The Unfolded Protein Response

The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K